Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNZ132-1-40 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| BNZ-1 | EXPERIMENTAL | IV PEGylated BNZ132-1-40 |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| BNZ132-1-40 | EXPERIMENTAL | PEGylated BNZ-1 for Injection |
| Name | Type | Description |
|---|---|---|
| BNZ132-1-40 | DRUG | Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15 |
| Placebo | DRUG | Normal Saline |
Inclusion Criteria: * Willing and able to consent and participate in the study. * Agrees not to receive any other investigational product or therapy while participating in this study. * Must be: * Currently using two forms of effective birth control (one of which is a barrier method) for the dur...
BNZ132-1-40 is an investigational monoclonal antibody being studied for use in healthy subjects and in patients with LGL leukemia or refractory cutaneous T-cell lymphoma (CTCL). It has been evaluated in early-phase clinical trials to assess safety, tolerability, and dosing.
BNZ132-1-40 is being developed by Equillium, Inc., a biopharmaceutical company. Equillium is publicly traded under the ticker symbol EQ on the Nasdaq stock exchange.
BNZ132-1-40 is in Phase 1 clinical development. All three clinical trials listed for the drug are Phase 1 studies that have been completed. It remains an investigational agent and has not been approved by regulatory authorities.
BNZ132-1-40 has been studied in three completed Phase 1 trials: NCT03046459, a first-in-human study in healthy subjects; NCT03239379, a multiple-dose study in healthy adults; and NCT03239392, a dose-ranging study in patients with LGL leukemia or refractory CTCL.
Yes, BNZ132-1-40 is also referred to as BNZ-1 in clinical trial records. The trial NCT03239392, which studied the drug in LGL leukemia and refractory CTCL, uses the name BNZ-1 in its title.